Video

Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer

The comprehensive review includes key developments in both clear cell and non-clear cell histology.

Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).

At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a phase 2 study in which the investigational HIF-2α inhibitor MK-6482 showed durable efficacy in patients with Von Hippel-Lindau–associated RCC and non-renal lesions.

In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.